Commit Biologics, a biotech company pioneering complement system activation, has appointed Thomas Montgomery Andresen as Chief Executive Officer (CEO), effective 16 March 2026.
Thomas, a biotech entrepreneur, brings over 20 years of experience building biotech ventures at the intersection of therapeutic innovation and bioengineering to the role. He most recently served as founding CEO of T-Cypher Bio, an Oxford, UK-based immunotherapy company. He also co-founded several biotech companies, including Flagship Pioneering-backed Torque Therapeutics and was founding director of DTU Health Tech at the Technical University of Denmark (DTU).
Thomas said: “Commit is redefining immunotherapy by activating the complement system – one of the immune system’s most potent, yet untapped weapons. Since the turn of the century, the immunotherapy field has produced a series of breakthrough modalities, from checkpoint inhibitors to CAR-Ts and T-cell engagers. Commit is at the forefront of what I firmly believe to be the next breakthrough modality: complement-powered immune engagers.
“The company’s preclinical data is outstanding, and its non-human primate data, in particular, gives me the strong conviction that these positive results will be replicated in the clinic.”
Commit is poised to nominate its first two clinical development candidates (DCs) in 2026, which will address key unmet needs in autoimmune disease and oncology. These DCs lead a broader pipeline targeting strategic clinical entry points, focusing on patients with compromised T-cell function, and indications where the differentiated mechanism of action offers new high-value treatment possibilities.
Anker Lundemose, Chairman of the Board at Commit Biologics, said: “Thomas’ rare combination of deep scientific expertise and strategic leadership as a serial biotech founder makes him exceptionally qualified to lead Commit into its next phase of growth.”